Goserelin
Zoladex (goserelin) is a protein pharmaceutical. Goserelin was first approved as Zoladex on 1989-12-29. The pharmaceutical is active against gonadotropin-releasing hormone receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Zoladex
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zoladex | New Drug Application | 2021-06-30 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9202 | Goserelin acetate implant, per 3.6 mg |
| S9560 | Home injectable therapy; hormonal therapy (e.g.; leuprolide, goserelin), including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
Clinical
Clinical Trials
112 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | C61 | 2 | 21 | 20 | 2 | 8 | 52 | |
| Infertility | D007246 | EFO_0000545 | — | 3 | 1 | 1 | 1 | 5 | |
| Kallmann syndrome | D017436 | Orphanet_478 | E23.0 | — | 1 | — | 1 | 3 | 5 |
| Female infertility | D007247 | EFO_0008560 | N97 | — | 1 | 1 | 1 | 1 | 3 |
| Fertilization in vitro | D005307 | — | — | — | 1 | 1 | 2 | ||
| Endometriosis | D004715 | EFO_0001065 | N80 | — | — | — | 2 | — | 2 |
| Ovarian reserve | D065851 | EFO_0004770 | — | — | — | 1 | — | 1 | |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | 1 | — | 1 |
| Amenorrhea | D000568 | N91.2 | — | — | — | 1 | — | 1 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 7 | 3 | — | — | 11 |
| Hypogonadism | D007006 | E23.0 | 1 | 2 | 1 | — | 6 | 10 | |
| Triple negative breast neoplasms | D064726 | — | — | 3 | — | — | 3 | ||
| Precocious puberty | D011629 | E22.8 | — | — | 1 | — | 1 | 2 | |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | 1 | — | 1 | 2 |
| Embryo transfer | D004624 | — | — | 1 | — | — | 1 | ||
| Ductal carcinoma breast | D018270 | — | 1 | 1 | — | — | 1 | ||
| Inflammatory breast neoplasms | D058922 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | — | 3 | — | — | — | 3 | ||
| Male breast neoplasms | D018567 | — | 1 | — | — | — | 1 | ||
| Olfaction disorders | D000857 | R43.0 | — | 1 | — | — | — | 1 | |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | 1 | — | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | G31.84 | — | 1 | — | — | — | 1 | |
| Hyperprolactinemia | D006966 | E22.1 | — | 1 | — | — | — | 1 | |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | 1 | — | — | — | 1 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | 1 | — | — | — | 1 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 2 | 2 |
| Ovulation induction | D010062 | — | — | — | — | 1 | 1 | ||
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | — | 1 | 1 | |
| Gonadal disorders | D006058 | — | — | — | — | 1 | 1 | ||
| Porphyrias | D011164 | EFO_0000665 | E80.20 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | GOSERELIN |
| INN | goserelin |
| Description | Goserelin is an organic molecular entity. |
| Classification | Protein |
| Drug class | prehormones or hormone-release stimulating peptides |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 65807-02-5 |
| RxCUI | 50610 |
| ChEMBL ID | CHEMBL1201247 |
| ChEBI ID | — |
| PubChem CID | 5311128 |
| DrugBank | DB00014 |
| UNII ID | 0F65R8P09N (ChemIDplus, GSRS) |
Target
Agency Approved
GNRHR
GNRHR
Organism
Homo sapiens
Gene name
GNRHR
Gene synonyms
GRHR
NCBI Gene ID
Protein name
gonadotropin-releasing hormone receptor
Protein synonyms
gnRH receptor, gnRH-R, gonadotropin-releasing hormone (type 1) receptor 1, leutinizing hormone releasing horomone receptor, leutinizing-releasing hormone receptor, luliberin receptor, type I GnRH receptor
Uniprot ID
Mouse ortholog
Gnrhr (14715)
gonadotropin-releasing hormone receptor (Q61611)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Zoladex - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,349 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
225 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more